Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    NCT00974584
Show Display Options
Rank Status Study
1 Completed A Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non Small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: GDC-0941;   Drug: bevacizumab;   Drug: carboplatin;   Drug: cisplatin;   Drug: paclitaxel;   Drug: pemetrexed

Indicates status has not been verified in more than two years